retatrutide type 2 diabetes trial dosing Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people retatrutide phase 2 trial results

Highlighted text about two NHS colleagues This story never happened

In the main per-protocol analyses, participants were followed from the index date to first mutually exclusive incidence of SIS, discontinuation of study drug (defined as more than 60 days without drug supply), initiation of other study drug, or switch to other glucose-lowering drug (defined as filling a prescription for any glucose-lowering drug other than the baseline treatment or metformin and not refilling the assigned drug for 60 days), death, or end of follow-up

GIP, or glucose-dependent insulinotropic polypeptide, enhances insulin secretion and may also directly influence fat storage and metabolism

Zepbound is a registered trademark of Eli Lilly

Was I supposed to force myself to eat even though I wasn't hungry

The glucagon receptor, again, appears to be the differentiator